Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140114 | 0.92 | TOP2A (0.37) | TOP2ATOP2BALDH1A1HTTMTNR1A | |
| SCHEMBL20140163 | 0.90 | TOP2A (0.36) | TOP2ATOP2BALDH1A1HTT | |
| SCHEMBL20139409 | 0.84 | TOP2A (0.36) | TOP2ATOP2BALDH1A1HTT | |
| SCHEMBL20140012 | 0.83 | TOP2A (0.35) | TOP2ATOP2B | |
| SCHEMBL20139635 | 0.79 | ALDH1A1 (0.36) | TOP2ATOP2BALDH1A1HTT | |
| SCHEMBL20140360 | 0.73 | — | — | |
| SCHEMBL20139974 | 0.69 | TOP2A (0.36) | TOP2ATOP2BALDH1A1 | |
| SCHEMBL20139978 | 0.69 | TOP2A (0.41) | TOP2ATOP2BALDH1A1HTTMTNR1A | |
| SCHEMBL20140293 | 0.68 | TOP2A (0.36) | TOP2ATOP2BALDH1A1HTT | |
| SCHEMBL20139480 | 0.66 | CHRNA7 (0.44) | TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | TOP2A 2707/4885TOP2B 2772/4885ALDH1A1 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.